DeepMed Research

WASHINGTON UNIVERSITY SCHOOL OF MEDICINE

🇺🇸United States

Country: 🇺🇸United States

Ownership: Private, Subsidiary

Established: 1891-01-01

Employees: 10K

Market Cap: -

Website: http://www.medschool.wustl.edu

Clinical Trials

CNS-Relapse Prevention in High-Risk Diffuse Large B-cell Lymphoma With Thiotepa-based Autologous Stem Cell Transplant

Phase 2

Recruiting

Conditions: Diffuse Large B Cell Lymphoma

Interventions: Drug: Thiotepa
Drug: Carmustine
Procedure: Autologous Stem Cell Transplant
Drug: Anthracycline-based induction chemotherapy

First Posted Date: 2024-11-14

Last Posted Date: 2025-03-17

Lead Sponsor: Washington University School of Medicine

Target Recruit Count: 36

Registration Number: NCT06687772

Locations: 🇺🇸
Washington University School of Medicine, Saint Louis, Missouri, United States

Let's Get REAL: Family Health Communication Tool in Pediatric Stem Cell Transplant and Cellular Therapy

Not Applicable

Recruiting

Conditions: Hematologic Malignancy
Solid Tumor
Sickle Cell Disease
Aplastic Anemia
Immune Deficiency
Metabolic Disorder

First Posted Date: 2024-11-14

Last Posted Date: 2024-11-28

Lead Sponsor: Washington University School of Medicine

Target Recruit Count: 60

Registration Number: NCT06689800

Locations: 🇺🇸
Washington University School of Medicine, Saint Louis, Missouri, United States

MK2 Inhibitor in Combination With mFOLFIRINOX for Untreated Metastatic Pancreatic Ductal Adenocarcinoma

Phase 1

Not yet recruiting

Conditions: Metastatic Pancreatic Ductal Adenocarcinoma
Pancreatic Cancer
Cancer of the Pancreas

Interventions: Drug: Zunsemetinib
Drug: mFOLFIRINOX

First Posted Date: 2024-10-18

Last Posted Date: 2025-05-18

Lead Sponsor: Washington University School of Medicine

Target Recruit Count: 51

Registration Number: NCT06648434

Locations: 🇺🇸
Washington University School of Medicine, Saint Louis, Missouri, United States

A Study of a Potential Disease Modifying Treatment in Individuals at Risk for or With a Type of Early Onset AD Caused by a Genetic Mutation

Phase 2

Recruiting

Conditions: Alzheimers Disease
Dementia
Alzheimers Disease, Familial

Interventions: Drug: Remternetug
Drug: Matching Placebo (Remternetug)

First Posted Date: 2024-10-17

Last Posted Date: 2025-04-01

Lead Sponsor: Washington University School of Medicine

Target Recruit Count: 280

Registration Number: NCT06647498

Locations: 🇺🇸
University of Pittsburgh, Pittsburgh, Pennsylvania, United States
🇺🇸
Butler Hospital, Providence, Rhode Island, United States
🇺🇸
Kerwin Research and Memory Center, Dallas, Texas, United States

and more 32 locations

Promotion of RSV Immunization Through Multiple Efforts

Phase 3

Active, not recruiting

Conditions: Pregnancy
Vaccination

First Posted Date: 2024-10-15

Last Posted Date: 2025-02-19

Lead Sponsor: Washington University School of Medicine

Target Recruit Count: 50

Registration Number: NCT06640868

Locations: 🇺🇸
Washington University in St. Louis, St Louis, Missouri, United States

PEP-CMV + Nivolumab for Newly Diagnosed Diffuse Midline Glioma/High-grade Glioma and Recurrent Diffuse Midline Glioma/High-grade Glioma, Medulloblastoma, and Ependymoma

Phase 1

Not yet recruiting

Conditions: Diffuse Midline Glioma
Diffuse Midline High-grade Glioma
Medulloblastoma
Ependymoma

Interventions: Biological: PEP-CMV vaccine
Biological: Tetanus booster
Biological: Nivolumab
Drug: Temozolomide

First Posted Date: 2024-10-15

Last Posted Date: 2025-01-14

Lead Sponsor: Washington University School of Medicine

Target Recruit Count: 68

Registration Number: NCT06639607

Locations: 🇺🇸
Washington University School of Medicine, Saint Louis, Missouri, United States
🇺🇸
Duke University Medical Center, Durham, North Carolina, United States
🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States

Language Matters: Exploring the Impact of Language Concordance on Fertility Treatment Progression

Not Applicable

Recruiting

Conditions: Infertility
Infertility (IVF Patients)
Infertility Assisted Reproductive Technology
Ovulation Ind

First Posted Date: 2024-10-15

Last Posted Date: 2025-03-28

Lead Sponsor: Washington University School of Medicine

Target Recruit Count: 70

Registration Number: NCT06636838

Locations: 🇺🇸
Washington University in St Louis, Saint Louis, Missouri, United States

Window of Opportunity Study of DSP-0390 in Gliomas

Early Phase 1

Recruiting

Conditions: Glioma, Malignant
Grade II Glioma
IDH Mutation

Interventions: Drug: DSP-0390

First Posted Date: 2024-10-10

Last Posted Date: 2025-04-06

Lead Sponsor: Washington University School of Medicine

Target Recruit Count: 20

Registration Number: NCT06636162

Locations: 🇺🇸
Washington University School of Medicine, Saint Louis, Missouri, United States

Maternal Maneuvers During Prolonged Labor

Not Applicable

Recruiting

Conditions: Labor Stage, First
Prolonged Labor

Interventions: Other: Circuit of maternal position changes during labor

First Posted Date: 2024-10-10

Last Posted Date: 2025-01-15

Lead Sponsor: Washington University School of Medicine

Target Recruit Count: 82

Registration Number: NCT06636149

Locations: 🇺🇸
Washington University Medicine, Saint Loius, Missouri, United States

64Cu-LLP2A for Imaging Hematologic Malignancies

Early Phase 1

Recruiting

Conditions: Multiple Myeloma
Low-Grade Lymphoma
Follicular Lymphoma
Marginal Zone Lymphoma
Lymphoplasmacytic Lymphoma
Small Lymphocytic Lymphoma
Chronic Lymphocytic Leukemia

Interventions: Drug: 64Cu-LLP2A
Device: PET/CT

First Posted Date: 2024-10-10

Last Posted Date: 2025-03-26

Lead Sponsor: Washington University School of Medicine

Target Recruit Count: 42

Registration Number: NCT06636175

Locations: 🇺🇸
Washington University School of Medicine, Saint Louis, Missouri, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy